“The Precision Target”
One of the more clinically studied GHRH analogues, notably researched for reducing visceral fat specifically, on top of general GH support.
Tesamorelin is a modified GHRH analogue engineered to resist rapid breakdown in the blood, giving it a longer effect than natural GHRH. Its most studied effect is a reduction in visceral (deep abdominal) fat specifically, separate from general GH support.
Yes. It's approved under the brand name Egrifta for reducing excess abdominal fat in people with HIV-associated lipodystrophy, making it one of the few peptides on this list with real regulatory approval.
Its approval is for a specific medical condition, not general weight loss. Broader use is extrapolated from that data, not directly proven for it.
It carries an FDA-reviewed safety and side-effect profile from clinical trials, which is more data than most peptides here have behind them.
Tesamorelin has gone through full clinical trials and FDA approval for a specific indication, making it one of the best-documented peptides in this entire library. Its use outside that approved context is far less studied.
The numbers are only half of it. The Blueprint covers exact dosing per peptide, proven stacks, and step-by-step injection instructions.
The complete peptide reference. 20+ compounds broken down, step-by-step instructions, stack breakdowns, troubleshooting, and a 30% sourcing discount code.
Learn More · $40